Indications
Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Composition
- Active substance
- elacestrant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Orserdu
- Active substance
- elacestrant
- ATC code
- L02BA
- Therapeutic area
- Breast Neoplasms
- Marketing authorisation holder
- Stemline Therapeutics B.V.